News

Eagles were recognized for the work in the classroom and out on the water CHESTNUT HILL, Mass. – 10 members of the Boston ...
Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...
FLAT ROCK, MI — Flat Rock Community Schools announced the top 10 graduates in the Flat Rock High School Class of 2025. The ...
We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation ...
Shares of Scholar Rock Holding ( SRRK 13.36%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 ...
Scholar Rock (NASDAQ: SRRK) has reported positive results from the phase 2 Embraze trial, demonstrating statistically ...
While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...
Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...
In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...
Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.
Shares of Scholar Rock climbed after the company disclosed what it called positive results from a Phase 2 study assessing its drug for weight loss. Shares rose 12% to $35.01 in pre-market trading ...
Scholar Rock (NASDAQ:SRRK) announced Wednesday that its lead candidate, apitegromab, in combination with Eli Lilly’s ...